A Mexico City Startup Achieves Historic SaMD Approval
A Mexico City-based startup has become the first in the Western Hemisphere to receive regulatory approval for its AI-powered diagnostic software classified as Class II Software as a Medical Device (SaMD) by COFEPRIS, Mexico’s FDA equivalent. This milestone offers a promising model for healthcare systems facing budget constraints and rising chronic disease rates.
In a small apartment outside Puebla, Maria Elena Hernandez records a 70-second video selfie on her smartphone. During this brief capture, AI algorithms analyze over 20 vital signs and biomarkers—such as blood pressure, heart rate, and oxygen levels—with medical-grade precision. The AI detects early signs of hypertension that conventional tests might miss for years, a critical breakthrough given that 65% of hypertension cases in Mexico go undiagnosed until emergencies occur.
Beyond collecting vital signs, the Medsi AI platform interprets them against comprehensive health data, medical literature, and generates personalized insights comparable to evaluations by medical specialists. It provides both patients and healthcare providers with accessible health reports and clinical-grade analyses within minutes.
The NAFTA Health Legacy
Mexico’s healthcare challenges are tied in part to the 1994 NAFTA agreement, which increased the availability of processed foods and sugary drinks, fueling one of the world’s most severe chronic disease epidemics. Combined with a genetic predisposition to Type 2 diabetes, socioeconomic disparities, and limited healthcare access, chronic diseases have surged dramatically.
Manuel Villalvazo, CEO and co-founder of Medsi AI, notes, “NAFTA brought economic opportunities, but it also brought sugary drinks to every corner store. Today, in rural Mexico, soft drinks are often cheaper and more accessible than clean water.” This has contributed to high rates of diabetes and hypertension, with 74% of deaths linked to non-communicable diseases.
Half of Mexico’s population lacks sufficient healthcare coverage, incurring some of the highest out-of-pocket costs globally. The situation in Mexico reflects challenges that may soon affect other North American healthcare markets, where budget cuts and chronic disease prevalence threaten care access. Villalvazo emphasizes that technology-enabled healthcare solutions like Medsi AI are becoming essential as traditional systems struggle to meet demand.
The Smartphone Medical Approach
The initial smartphone video capture is only the start. Medsi’s AI decodes subtle changes in light absorption from a smartphone camera to extract detailed physiological data without skin contact or special equipment. It measures heart rate, blood pressure, respiratory rate, oxygen saturation, and stress indicators.
The platform’s proprietary Retrieval-Augmented Generation layer—protected by pending patents in Mexico and the U.S.—moves beyond pattern recognition to clinical reasoning. It assesses complex relationships between health parameters, medical history, and lifestyle context to produce insights akin to a team of medical specialists.
Jorge Hinojosa, COO and co-founder, explains, “Our AI can assess cardiovascular risk, diabetes markers, medication interactions, and preventive care recommendations simultaneously, adjusting communication for patients or healthcare providers.”
Clinical Validation and Real-World Impact
Medsi AI’s technology has been validated through clinical trials and corporate wellness programs in Mexico. It boasts over 60% user engagement after 30 days—three times higher than typical healthcare apps. Consistent platform use correlates with significant improvements in blood pressure and blood glucose control.
Early detection of chronic diseases through Medsi AI allows intervention well before traditional diagnosis, improving treatment effectiveness and affordability. The AI helps healthcare providers prioritize referrals, functioning like a resident physician with instant access to thousands of cases, which is crucial in resource-limited settings.
Corporate clients report reduced absenteeism and higher productivity, addressing economic impacts tied to chronic illness. The platform also uses behavioral science and personalized gamification to adapt its approach based on individual motivation patterns.
Strategic Investment and Market Validation
Laboratorios Sanfer, Mexico’s largest private pharmaceutical company, led Medsi’s $3 million Seed 1 funding round. Supported by global investors CDPQ and General Atlantic, this backing underscores confidence in Medsi’s approach.
Ricardo Amtmann Aguilar, CEO of Sanfer, states, “Investing in technology that makes preventive healthcare accessible through smartphones helps tackle Mexico’s pressing health challenges and fosters a sustainable healthcare model.”
Interest in AI-driven healthcare solutions is growing sharply across North America. In 2024, $5.6 billion was invested in AI healthcare companies, nearly tripling the previous year’s figure. Digital health funding reached $5.3 billion in Q1 2025, up 47% quarter-over-quarter.
Regulatory Breakthrough Opens New Possibilities
Medsi’s Class II SaMD approval confirms that smartphone-based software can meet the rigorous standards of hospital-grade medical devices for diagnosis and monitoring. This sets a precedent for AI clinical reasoning capabilities to be recognized as trustworthy medical tools.
Villalvazo explains, “Our platform can independently perform medical diagnosis and monitoring functions, meeting the same standards as traditional devices.” Achieving this required extensive clinical validation, quality management, and ongoing surveillance.
The approval creates strong competitive advantages in a $46 billion primary care and screening market. Leveraging existing smartphone infrastructure allows scalable, cost-effective population health management, valuable for resource-strapped healthcare systems.
Hinojosa adds, “We’re enhancing healthcare by extending the reach and impact of existing providers, which is vital where physician shortages and specialist access are major challenges.”
The Health 3.0 Approach
Medsi AI embodies what experts call Health 3.0—AI that enhances rather than replaces human medical expertise. Villalvazo comments, “Our system delivers comprehensive analyses typically requiring a specialist team, instantly, in multiple languages, and customized to each patient’s health profile and cultural context.”
With aging populations, rising chronic disease, and constrained budgets worldwide, this technology offers a scalable model for preventive care. Mexico’s experience with diet-driven health challenges illustrates both risks and potential solutions applicable globally.
“By democratizing access to advanced preventive care through devices people already own, we address critical societal needs and build a sustainable path forward for healthcare,” Villalvazo concludes.
For healthcare professionals interested in AI applications and training, resources are available at Complete AI Training.
Your membership also unlocks:
